Table 4 Thrombotic complications during... | American Society of Hematology

Table 4

Thrombotic complications during lepirudin treatment

Patient	Sex	Age, y	HIT-T	Anti-PF4/H antibodies		CrCl, mL/min	Lepirudin treatment			Anticoagulation at first monitoring	Dose adjustments			Event
				Anti-PF4/H antibodies			Dose, mg kg⁻¹ hr⁻¹		Length, days		↑	↓	Stop*	Event
				Titer	OD		Start	End	Length, days		n	n	n	Localization	Day
A	Male	36.0	Arterial	32	2.426	64	0.100	0.014	7	Over	3	5	2	Amputation, distal	7
B	Female	73.5	Vein bypass	16	2.129	35	0.150	0.003	17	Over	3	13	3	Amputation, proximal	6
C	Male	50.2	Arterial	64	2.801	95	0.100	0.070	5	Over	0	3	0	Amputation, distal	4
D	Female	88.7	Arterial	16	2.260	24	0.020	0.020	7	Target	0	0	2	DVT; PE	5; 7

Patient	Sex	Age, y	HIT-T	Anti-PF4/H antibodies		CrCl, mL/min	Lepirudin treatment			Anticoagulation at first monitoring	Dose adjustments			Event
				Anti-PF4/H antibodies			Dose, mg kg⁻¹ hr⁻¹		Length, days		↑	↓	Stop*	Event
				Titer	OD		Start	End	Length, days		n	n	n	Localization	Day
A	Male	36.0	Arterial	32	2.426	64	0.100	0.014	7	Over	3	5	2	Amputation, distal	7
B	Female	73.5	Vein bypass	16	2.129	35	0.150	0.003	17	Over	3	13	3	Amputation, proximal	6
C	Male	50.2	Arterial	64	2.801	95	0.100	0.070	5	Over	0	3	0	Amputation, distal	4
D	Female	88.7	Arterial	16	2.260	24	0.020	0.020	7	Target	0	0	2	DVT; PE	5; 7

HIT-T indicates HIT with thrombosis; OD, optical density; CrCl, creatinine clearance; Over, TT/aPTT above therapeutic ranges; Target, TT/aPTT within therapeutic ranges; Vein bypass, occlusion of a greater saphenous vein bypass in the context of chronic peripheral arterial occlusive disease; Amputation, limb amputation (distal, below-knee; proximal, above-knee); DVT, deep vein thrombosis; and PE, pulmonary embolism.

Stop indicates instances in which lepirudin infusion was temporarily interrupted for 2 hours or longer.

View Large

This Feature Is Available To Subscribers Only